Glucagon-like peptide 1-based therapies and risk of pancreatitis: A self-controlled case series analysis

Xiaochun Li, Zuoyi Zhang, Jon Duke

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Purpose: Previous studies have suggested a link between glucagon-like peptide 1 (GLP-1)-based therapies and acute pancreatitis, while other studies have found no association. Because differences in diabetes severity may confound this relationship, a self-controlled case series (SCCS) analysis has been suggested as a means to control for individual-level confounding. Methods: We evaluated the relationship between GLP-1-based therapies and pancreatitis by SCCS method using a large observational database. We calculated the incidence density ratio of pancreatitis for exposure versus non-exposure to each drug. To examine the robustness of our findings, we performed sensitivity analyses by varying risk windows, using two pancreatitis definitions and including incident pancreatitis or all occurrences. Results: From dispensing data on 1.2 million patients, we found 7992 sitagliptin-exposed patients and 3552 exenatide-exposed patients between 2004 and 2009. Using an ICD9/CPT-based case definition of pancreatitis, we identified 207 sitagliptin and 82 exenatide cases. Augmenting this definition with laboratory criteria increased our cohort to 245 sitagliptin and 96 exenatide cases. For sitagliptin and exenatide cases, respectively, the mean duration of observation was 5.2 and 5.5years, and the mean duration of drug exposure was 0.7 and 0.5years. For all analyses (including different pancreatitis definitions, risk periods, and incident or recurrent events), the incidence density ratios for development of pancreatitis during exposure versus non-exposure ranged from 0.68 to 1.46, with all having 95% confidence intervals containing 1. Conclusions: We found no association between the use of GLP-1-based therapies and pancreatitis using SCCS analysis in a large observational database.

Original languageEnglish
Pages (from-to)234-239
Number of pages6
JournalPharmacoepidemiology and Drug Safety
Volume23
Issue number3
DOIs
StatePublished - 2014

Fingerprint

Glucagon-Like Peptide 1
Pancreatitis
Therapeutics
Databases
Incidence
Pharmaceutical Preparations
Observation
Confidence Intervals
exenatide
Sitagliptin Phosphate

Keywords

  • Electronic observational databases
  • GPL-1
  • Pancreatitis
  • Pharmacoepidemiology
  • Safety surveillance
  • Self-controlled case series

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Epidemiology
  • Medicine(all)

Cite this

Glucagon-like peptide 1-based therapies and risk of pancreatitis : A self-controlled case series analysis. / Li, Xiaochun; Zhang, Zuoyi; Duke, Jon.

In: Pharmacoepidemiology and Drug Safety, Vol. 23, No. 3, 2014, p. 234-239.

Research output: Contribution to journalArticle

@article{c4dc89a6fa9b4b7982fe9f326627425f,
title = "Glucagon-like peptide 1-based therapies and risk of pancreatitis: A self-controlled case series analysis",
abstract = "Purpose: Previous studies have suggested a link between glucagon-like peptide 1 (GLP-1)-based therapies and acute pancreatitis, while other studies have found no association. Because differences in diabetes severity may confound this relationship, a self-controlled case series (SCCS) analysis has been suggested as a means to control for individual-level confounding. Methods: We evaluated the relationship between GLP-1-based therapies and pancreatitis by SCCS method using a large observational database. We calculated the incidence density ratio of pancreatitis for exposure versus non-exposure to each drug. To examine the robustness of our findings, we performed sensitivity analyses by varying risk windows, using two pancreatitis definitions and including incident pancreatitis or all occurrences. Results: From dispensing data on 1.2 million patients, we found 7992 sitagliptin-exposed patients and 3552 exenatide-exposed patients between 2004 and 2009. Using an ICD9/CPT-based case definition of pancreatitis, we identified 207 sitagliptin and 82 exenatide cases. Augmenting this definition with laboratory criteria increased our cohort to 245 sitagliptin and 96 exenatide cases. For sitagliptin and exenatide cases, respectively, the mean duration of observation was 5.2 and 5.5years, and the mean duration of drug exposure was 0.7 and 0.5years. For all analyses (including different pancreatitis definitions, risk periods, and incident or recurrent events), the incidence density ratios for development of pancreatitis during exposure versus non-exposure ranged from 0.68 to 1.46, with all having 95{\%} confidence intervals containing 1. Conclusions: We found no association between the use of GLP-1-based therapies and pancreatitis using SCCS analysis in a large observational database.",
keywords = "Electronic observational databases, GPL-1, Pancreatitis, Pharmacoepidemiology, Safety surveillance, Self-controlled case series",
author = "Xiaochun Li and Zuoyi Zhang and Jon Duke",
year = "2014",
doi = "10.1002/pds.3542",
language = "English",
volume = "23",
pages = "234--239",
journal = "Pharmacoepidemiology and Drug Safety",
issn = "1053-8569",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - Glucagon-like peptide 1-based therapies and risk of pancreatitis

T2 - A self-controlled case series analysis

AU - Li, Xiaochun

AU - Zhang, Zuoyi

AU - Duke, Jon

PY - 2014

Y1 - 2014

N2 - Purpose: Previous studies have suggested a link between glucagon-like peptide 1 (GLP-1)-based therapies and acute pancreatitis, while other studies have found no association. Because differences in diabetes severity may confound this relationship, a self-controlled case series (SCCS) analysis has been suggested as a means to control for individual-level confounding. Methods: We evaluated the relationship between GLP-1-based therapies and pancreatitis by SCCS method using a large observational database. We calculated the incidence density ratio of pancreatitis for exposure versus non-exposure to each drug. To examine the robustness of our findings, we performed sensitivity analyses by varying risk windows, using two pancreatitis definitions and including incident pancreatitis or all occurrences. Results: From dispensing data on 1.2 million patients, we found 7992 sitagliptin-exposed patients and 3552 exenatide-exposed patients between 2004 and 2009. Using an ICD9/CPT-based case definition of pancreatitis, we identified 207 sitagliptin and 82 exenatide cases. Augmenting this definition with laboratory criteria increased our cohort to 245 sitagliptin and 96 exenatide cases. For sitagliptin and exenatide cases, respectively, the mean duration of observation was 5.2 and 5.5years, and the mean duration of drug exposure was 0.7 and 0.5years. For all analyses (including different pancreatitis definitions, risk periods, and incident or recurrent events), the incidence density ratios for development of pancreatitis during exposure versus non-exposure ranged from 0.68 to 1.46, with all having 95% confidence intervals containing 1. Conclusions: We found no association between the use of GLP-1-based therapies and pancreatitis using SCCS analysis in a large observational database.

AB - Purpose: Previous studies have suggested a link between glucagon-like peptide 1 (GLP-1)-based therapies and acute pancreatitis, while other studies have found no association. Because differences in diabetes severity may confound this relationship, a self-controlled case series (SCCS) analysis has been suggested as a means to control for individual-level confounding. Methods: We evaluated the relationship between GLP-1-based therapies and pancreatitis by SCCS method using a large observational database. We calculated the incidence density ratio of pancreatitis for exposure versus non-exposure to each drug. To examine the robustness of our findings, we performed sensitivity analyses by varying risk windows, using two pancreatitis definitions and including incident pancreatitis or all occurrences. Results: From dispensing data on 1.2 million patients, we found 7992 sitagliptin-exposed patients and 3552 exenatide-exposed patients between 2004 and 2009. Using an ICD9/CPT-based case definition of pancreatitis, we identified 207 sitagliptin and 82 exenatide cases. Augmenting this definition with laboratory criteria increased our cohort to 245 sitagliptin and 96 exenatide cases. For sitagliptin and exenatide cases, respectively, the mean duration of observation was 5.2 and 5.5years, and the mean duration of drug exposure was 0.7 and 0.5years. For all analyses (including different pancreatitis definitions, risk periods, and incident or recurrent events), the incidence density ratios for development of pancreatitis during exposure versus non-exposure ranged from 0.68 to 1.46, with all having 95% confidence intervals containing 1. Conclusions: We found no association between the use of GLP-1-based therapies and pancreatitis using SCCS analysis in a large observational database.

KW - Electronic observational databases

KW - GPL-1

KW - Pancreatitis

KW - Pharmacoepidemiology

KW - Safety surveillance

KW - Self-controlled case series

UR - http://www.scopus.com/inward/record.url?scp=84895474209&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895474209&partnerID=8YFLogxK

U2 - 10.1002/pds.3542

DO - 10.1002/pds.3542

M3 - Article

C2 - 24741695

AN - SCOPUS:84895474209

VL - 23

SP - 234

EP - 239

JO - Pharmacoepidemiology and Drug Safety

JF - Pharmacoepidemiology and Drug Safety

SN - 1053-8569

IS - 3

ER -